Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06914648

The DRAGON PLC Trial - An International Multicenter Randomized Controlled Trial to Compare Combined Portal and Hepatic Vein Embolization (PVE/HVE) With PVE Alone in Primary Liver Cancers.

Led by Maastricht University · Updated on 2025-05-15

358

Participants Needed

55

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are investigating whether combining portal vein embolization (PVE) with hepatic vein embolization (HVE) improves the chances of liver surgery and overall survival in patients with initially unresectable primary liver cancers, including hepatocellular carcinoma and cholangiocarcinoma. The trial aims to see if this combined approach increases liver growth and makes surgery possible within 3 weeks, and whether it improves survival over 5 years compared to standard PVE alone. Participants will receive either standard PVE or the combined PVE and HVE procedure. PVE involves blocking blood flow to part of the liver to encourage growth of the remaining liver, while HVE adds blockage of the hepatic vein during the same session. These procedures are done using specific techniques like a transhepatic approach for PVE and transjugular or transfemoral approaches for HVE. The study compares these two approaches to see which better supports liver growth and surgery readiness. Throughout the study, participants will undergo regular imaging to check liver growth and resectability. Researchers will monitor survival outcomes for up to 5 years after the embolization procedures. The main outcomes measured include the proportion of patients able to have surgery within 3 weeks and overall survival at 5 years. The study also tracks safety and liver function to ensure participants' well-being during and after treatment.

CONDITIONS

Brief Title

The Dragon PLC Trial (DRAGON-PLC)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis of primary liver cancer, specifically intrahepatic cholangiocarcinoma (iCCC), perihilar cholangiocarcinoma (pCCC), or hepatocellular carcinoma (HCC)
  • Requiring portal vein embolization (PVE) due to future liver remnant (FLR) volume less than 30% in normally functioning livers
  • Requiring PVE due to FLR less than 40% in livers with potentially impaired function (e.g., prior systemic therapy or bile duct drainage)
  • Requiring PVE due to FLR less than 50% in livers with severely impaired function from liver cirrhosis (maximum Child-Pugh A5)
  • Alternatively, FLR function on hepatobiliary scintigraphy (HEBIS) less than 2.7 %/min/m2
  • Age 18 years or older
  • Able to understand the trial and provide informed consent
Not Eligible

You will not qualify if you...

  • Liver cirrhosis with Child-Pugh score of B or C
  • Presence of portal hypertension
  • Presence of cholangitis
  • Pregnant women
  • Premenopausal females not able or willing to commit to contraception (long-acting reversible or hormonal)
  • Patients deemed unresectable due to prohibitive comorbidities by local multidisciplinary team
  • Patients with hepatic malignancies other than iCCC, pCCC, or HCC
  • Anatomical infeasibility of PVE/HVE
  • Presence of non-resectable or non-ablatable extrahepatic metastatic disease
  • Unable to understand study information, instructions, or provide informed consent

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) for eligibility assessment

Treatment

Duration - Up to 3 weeks until assessment for surgical resectability

Participants undergo either Portal Vein Embolization (PVE) alone or Combined Portal and Hepatic Vein Embolization (PVE/HVE) to increase future liver remnant volume and function before surgery.

1 visit for embolization procedure and follow-up visits until resectability assessment

Follow-up

Duration - Up to 5 years

Participants are monitored for overall survival and quality of life after treatment and potential surgery.

Periodic follow-up visits over 5 years for survival and quality of life assessments

Trial Site Locations

Total: 55 locations

1

Yale School of Medicine Hospital

New Haven, Connecticut, United States, 06510

Not Yet Recruiting

2

Rush University Medical Center

Chicago, Illinois, United States, 60612

Not Yet Recruiting

3

Mayo Clinic

Rochester, Minnesota, United States, 55905

Not Yet Recruiting

4

Memorial Sloan Kettering Cancer Center

New York, New York, United States, 10065

Not Yet Recruiting

5

Cleveland Clinic

Cleveland, Ohio, United States, 44195

Not Yet Recruiting

6

Monash Medical Center

Melbourne, Australia

Not Yet Recruiting

7

Medical University of Vienna

Vienna, State of Vienna, Austria, 1090

Not Yet Recruiting

8

Social Center South

Vienna, State of Vienna, Austria, 1100

Not Yet Recruiting

9

Erasmus Hospital

Brussels, Brussels Capital, Belgium, 1070

Not Yet Recruiting

10

UZ Antwerpen

Antwerp, Edegem, Belgium, 2650

Not Yet Recruiting

11

UZ Gent

Ghent, Gent, Belgium, 9000

Not Yet Recruiting

12

CHU Liège

Liège, Liège, Belgium, 4000

Actively Recruiting

13

CHU-UCL Namur site Godinne (UCLouvain)

Yvoir, Namen, Belgium, 5530

Not Yet Recruiting

14

Cliniques Universitaires Saint Luc, UCLouvain

Brussels, Belgium, 1200

Not Yet Recruiting

15

Jessa Hospital

Hasselt, Belgium, 3500

Not Yet Recruiting

16

UZ Brussel

Jette, Belgium, 1090

Not Yet Recruiting

17

AZ Groeninge Hospital Kortrijk

Kortrijk, Belgium, 8500

Not Yet Recruiting

18

Foothills Medical Center

Calgary, Alberta, Canada

Not Yet Recruiting

19

Vancouver General Hospital

Vancouver, British Columbia, Canada

Not Yet Recruiting

20

Queen Elizabeth II Health Sciences Center

Halifax, Nova Scotia, Canada

Not Yet Recruiting

21

Juravinski Hospital and Cancer Centre

Hamilton, Ontario, Canada

Not Yet Recruiting

22

Kingston Health Sciences Centre

Kingston, Ontario, Canada

Not Yet Recruiting

23

London Health Sciences Centre

London, Ontario, Canada

Not Yet Recruiting

24

St. Joseph's Health Centre

Toronto, Ontario, Canada

Not Yet Recruiting

25

Sunnybrook Hospital

Toronto, Ontario, Canada

Not Yet Recruiting

26

University Health Network/TGH

Toronto, Ontario, Canada

Not Yet Recruiting

27

Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke, Quebec, Canada

Not Yet Recruiting

28

Centre Hospitalier de l'Université de Montréal

Montreal, Canada

Not Yet Recruiting

29

McGill University Health Centre, Montreal

Montreal, Canada

Not Yet Recruiting

30

L'Hopital d'Ottawa

Ottawa, Canada

Not Yet Recruiting

31

Royal University Hospital

Saskatoon, Canada

Not Yet Recruiting

32

Universitätklinikum Köln

Cologne, Germany

Not Yet Recruiting

33

Universitätklinikum Dresden

Dresden, Germany

Not Yet Recruiting

34

Universitätklinikum Hannover

Hanover, Germany

Not Yet Recruiting

35

Ospedale San Raffaele

Milan, Italy

Not Yet Recruiting

36

Maastricht Universitair Medisch Centrum+

Maastricht, Limburg, Netherlands, 6229HX

Not Yet Recruiting

37

Amsterdam UMC, location VUMC

Amsterdam, North Holland, Netherlands

Not Yet Recruiting

38

Maxima Medisch Centrum

Eindhoven, Netherlands

Not Yet Recruiting

39

Universitair Medisch Centrum Groningen

Groningen, Netherlands

Not Yet Recruiting

40

Leiden Universitair Medisch Centrum

Leiden, Netherlands

Not Yet Recruiting

41

University Hospital Oslo

Oslo, Norway

Not Yet Recruiting

42

University Hospital Linköping

Linköping, Sweden

Not Yet Recruiting

43

Karolinska University Hospital Stockholm

Stockholm, Sweden

Not Yet Recruiting

44

Cantonal Hospital Winterthur

Winterthur, Canton of Zurich, Switzerland

Not Yet Recruiting

45

Claraspital Basel

Basel, Switzerland

Not Yet Recruiting

46

Universitätsspital Basel

Basel, Switzerland

Not Yet Recruiting

47

CHUV - Lausanne University Hospital

Lausanne, Switzerland

Not Yet Recruiting

48

Hirslanden Klinik St. Anna

Lucerne, Switzerland

Not Yet Recruiting

49

Hirslanden Klinik

Zurich, Switzerland

Not Yet Recruiting

50

Belfast Health and Social Care Trust

Belfast, United Kingdom

Not Yet Recruiting

51

Queen Elizabeth Hospital

Birmingham, United Kingdom

Not Yet Recruiting

52

Aintree University Hospital

Liverpool, United Kingdom

Not Yet Recruiting

53

Kings college Hospital

London, United Kingdom

Not Yet Recruiting

54

Oxford University Hospitals NHS Foundation Trust

Oxford, United Kingdom

Not Yet Recruiting

55

University Hospital Southampton

Southampton, United Kingdom

Not Yet Recruiting

Loading map...

Research Team

F

Fenna A van der Zijden, MSc Technical Medicine

S

Sinead James, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Evaluation of Diagnostic Value of 18F-T2 PET/ CT Imaging for...

Clear Cell Renal Cell Cancer (ccRCC)

Actively Recruiting

1 location

[68Ga]Ga-FAPI-46 Positron Emission Tomography in Pancreatico...

Pancreatic Cancer

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here